  
Recombinant yeast vaccines induce protective cell-mediated immunity
Last Updated: 2001-04-30 17:09:53 EDT (Reuters Health)
LONDON (Reuters Health) - Whole recombinant yeast vaccines can activate dendritic cells (DCs) and induce protective cell-mediated immunity, according to a report published in the May issue of Nature Medicine.
Dr. Richard C. Duke, from the University of Colorado Health Sciences Center in Denver, and colleagues tested the immunogenicity of recombinant Saccharomyces cerevisiae yeast vaccines engineered to express tumor or HIV-1 antigens.
The researchers found that vaccinated mice showed vigorous antigen-specific cytotoxic T lymphocyte responses, including those that mediate tumor protection. In addition, the yeast stimulated DC maturation and production of interleukin-12, and it led to efficient priming of MHC class I- and class II-restricted, antigen-specific T-cell responses.
"The recombinant-yeast-based vaccine approach integrates efficient antigen delivery with DC activation in a powerful vaccine formulation that does not require accessory adjuvant components," the investigators point out.
The current findings suggest that "recombinant yeast-based vaccine vectors might provide a powerful strategy for the induction of cell-mediated immunity directed against a variety of infectious diseases and cancer targets," Dr. Duke's team concludes.
Nat Med 2001;7:625-629.
-London Newsroom +44 20 7542 7986
|
Copyright 2001 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without prior written consent of Reuters Limited. Reuters Limited shall not be liable for any error or delays in the content, or for any actions taken in reliance thereon.
|
|
 Back To HIV Wellness Center
| 
